ATOS — Atossa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Atossa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.6 | -27 | -30.1 | -25.5 | -34.8 |
| Depreciation | |||||
| Non-Cash Items | 4.83 | 7.12 | 8.35 | 4.01 | 2.65 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.719 | -0.928 | 0.776 | 0.448 | 2.35 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -16.5 | -20.8 | -20.9 | -21 | -29.8 |
| Capital Expenditures | -0.009 | -0.027 | -0.014 | -0.019 | -0.023 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -4.7 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.009 | -4.73 | -0.014 | -0.019 | -0.023 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 113 | 0 | -1.48 | 3.67 | 0 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 96.8 | -25.5 | -22.4 | -17.4 | -29.8 |